'N of 1' ther­a­pies ad­dressed in draft FDA guid­ance

Rec­og­niz­ing the pace at which drug de­vel­op­ers are mov­ing ever fur­ther in­to in­di­vid­u­al­ized med­i­cine, the FDA has is­sued a draft guid­ance ad­dress­ing sub­mis­sion process­es for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.